Chemokine (C-X3-C motif ) ligand 1 (CX 3 CL1, also known as fractalkine) and its receptor chemokine (C-X3-C motif ) receptor 1 (CX 3 CR1) are widely expressed in immune cells and non-immune cells throughout organisms. However, their expression is mostly cell typespecific in each tissue. CX 3 CR1 expression can be found in monocytes, macrophages, dendritic cells, T cells, and natural killer (NK) cells. Interaction between CX 3 CL1 and CX 3 CR1 can mediate chemotaxis of immune cells according to concentration gradient of ligands. CX 3 CR1 expressing immune cells have a main role in either pro-inflammatory or antiinflammatory response depending on environmental condition. In a given tissue such as bone marrow, brain, lung, liver, gut, and cancer, CX 3 CR1 expressing cells can maintain tissue homeostasis. Under pathologic conditions, however, CX 3 CR1 expressing cells can play a critical role in disease pathogenesis. Here, we discuss recent progresses of CX 3 CL1/CX 3 CR1 in major tissues and their relationships with human diseases.
Immune cells including monocytes in our body are circulating through blood flow or lymph vessels. When inflammation occurs, these immune cells need to be recruited into inflamed tissue to alleviate the inflamed condition. At this moment, immune cells can move to the inflamed site through chemotaxis by chemokines and their receptors expressed by cells. CX 3 CR1 is a member of seven-transmembrane G-protein coupled receptor (GPCR). It is a receptor for its sole ligand, CX 3 CL1, also known as fractalkine or neurotactin (Fig. 1A) (1) . CX 3 CR1 and its function in immune cells have been extensively studied for over 20 years. CX 3 CL1 is a transmembrane protein with an extended and highly glycosylated mucin-like stem (2) . Proteolytic cleavage by metalloprotease ADAM10 generates various soluble forms of CX 3 CL1 (3). Under inflammation, CX 3 CL1 shedding is promoted by ADAM17 (4) . Immune cells that express CX 3 CR1 include monocyte, macrophage, microglia, T helper (Th) 1, CD8 + T effector/memory cell, NK cell, γδ T cell, and dendritic cell (DC). Both CX 3 CL1 and CX 3 CR1 are expressed throughout the body. However, their expression is highly cell type-specific depending on organs and tissues. For instance, CX 3 CR1 in the brain is mostly expressed on microglia. In gut and blood, CX 3 CR1 expression is restricted to macrophages and monocytes, respectively (5, 6) . The expression of ligand CX 3 CL1 has been found in neurons, intestinal epithelium, and inflamed endothelium. The major role of CX 3 CR1 in immune cells is to recognize and enter inflamed tissue according to CX 3 CL1 gradient to initiate innate immune system (Fig. 1B) (7) . This step is also important for continuing immune response through type 1 adaptive immunity. Thus, interaction between CX 3 CL1 and CX 3 CR1 is one initial step in host defense for monocyte crawling or "patrolling" in the lumen of blood vessels. CX 3 CR1 expressing immune cells play significant roles in pathological diseases at specific tissues in human. This implies that CX 3 CR1 expressing immune cells have tissue-specific roles. In the brain, CX 3 CL1/CX 3 CR1 signaling can modulate the production of cytokines by microglia cells (8) . It has been reported that CX 3 CL1/CX 3 CR1 signaling is associated with Alzheimer's disease (9) . In the liver, CX 3 CR1 is expressed in monocytes, CD8 + T cells, and natural killer (NK) cells. Besides immune cells, it is highly expressed in regenerated epithelial cells in bile duct-like structures as well as inflammatory sites (2) . It has been verified that CX 3 CR1 is mainly expressed on lamina propria macrophage in the gut and on circulating monocyte in blood (5) . In this review, we will focus on tissue-specific role of CX 3 CR1 expressing immune cells and their relationships with human diseases.
BONE MARROW AND IMMUNE SYSTEM
Level of CX 3 CR1 expressed on monocytes is increased with maturation in bone marrow. It is inversely correlated with Ly6C marker and CCR2 in the blood (10) . CX 3 CR1 can reduce the motility of Ly6C high monocytes in the bone marrow, thereby controlling their release. CX 3 CR1-CX 3 CL1 axis plays a role in the differentiation of both osteoblasts and osteoclasts (11) . In patients with idiopathic thrombocytopenic purpura, CD8 + T cells inhibit megakaryocyte apoptosis, leading to impaired platelet production (12) . CX 3 CR1 expression in CD8 + T cells have been increased in bone marrow. This might be related to T cell recruitment from peripheral blood (13 
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+ NK cells are accumulated in the bone marrow during poly(I:C)-induced hepatitis inflammation (19) . CX 3 CR1 expression on NK cells mediates their migration to the central nervous system (CNS) from the periphery (20 Figure 1 . CX 3 CR1-CX 3 CL1 signaling pathway and migration process of immune cells via their interactions. (A) CX 3 CL1/fractalkine, a transmembrane protein with O-glycosylated mucin-like stem, is expressed on the surface of immune cells and non-immune cells. Soluble forms of CX 3 CL1 can be made after proteolytic cleavage by metalloprotease ADAM 10/17. Both membrane bound and soluble forms of CX 3 CL1 can bind to CX 3 CR1. CX 3 CR1 is seven-transmembrane G-protein coupled receptor. The complex of CX 3 CL1-CX 3 CR1 can activate NF-κB or CREB signaling pathway which promotes the secretion of inflammatory cytokines. (B) CX 3 CL1 is expressed on the surface of endothelial cells near inflamed tissues. CX 3 CL1 induces chemotaxis to promote recruitment of CX 3 CR1 expressing immune cells. Monocytes flowing through blood stream will encounter and recognize CX 3 CL1 on the endothelium near inflamed tissues. As CX 3 CL1-CX 3 CR1 complex is formed, monocytes are ready to enter inflamed tissues and then enter diapedesis between junctions of endothelial cells. In this process, monocytes will undergo maturation and differentiate into macrophages. Mature macrophages can relieve inflamed conditions. cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PLC, phospholipase C; MEK, methyl ethyl ketone; PI3K, phosphoinositide 3-kinase; IKK, IκB kinase; CREB, cAMP response element binding protein.
In the sera and synovial fluids of patients with rheumatoid arthritis (RA), concentration of CX 3 CL1 is higher compared with other types of arthritis (21) . CX 3 CL1 can be expressed by synovial tissue macrophages, DC, fibroblast-like synoviocytes as well as by vessel endothelial cells. Further, inflammatory cytokines such as tumor necrosis factor (TNF)-α or interferon (IFN)-γ upregulates the expression of membrane-bound CX 3 CL1 as well as the release of soluble CX 3 CL1 via ADAM17 (22) . Increased CX 3 CL1 expression contributes to the infiltration of inflammatory cells expressing CX 3 CR1 into affected joints including CD14 + or CD16 + macrophages, DCs, and T cells (23) . Blockade of CX 3 CL1 by a monoclonal antibody significantly reduces synovial inflammation and joint bone loss in the murine collageninduced arthritis (24) . Consistent with this, CX 3 CR1-deficient mice demonstrated decreased inflammation compared to the changes seen in wild-type mice (25) . These results suggested that inhibition of CX 3 CL1-CX 3 CR1 axis could be one of possible targets for RA. A clinical trial of monoclonal antibody against CX 3 CL1 in patients with RA has demonstrated promising efficacy in patients with active RA who were intolerant of harsh treatment with methotrexate or TNF inhibitors (26) .
BLOOD VESSEL SYSTEM AND ATHEROSCLEROSIS
CX 3 CR1 is expressed in vascular endothelial cells and monocytes/macrophages (Fig. 2) . When CX 3 CR1-expressing cells are activated by CX 3 CL1, hypoxia-inducible factor (HIF)-1α and mitogen-activated protein kinase (MAPK) are increased in endothelial cells. The production of vascular endothelial growth factor (VEGF) is also increased, thereby promoting cellular proliferation and formation of neo-vessel (27) . Deficient CX 3 CR1 signals can reduce binding of monocyte with injured endothelium, resulting in decreased adherence (28). In limb ischemia, human CD14 + monocyte, one of pro-angiogenic monocytes, is a CX 3 CR1-expressing cell involved in the formation of extracellular matrix and vascular remodeling by producing cytokines and growth factors involved in angiogenesis (29). Although most blood monocytes express CX 3 CR1, its expression is significantly greater in CD14 + CD16 + cells (5). CD14 + CD16 + cells can move along blood vessel walls and then differentiate into macrophages or DCs to control inflammation. CX 3 CR1 expression on CD4 + and CD8 + T cells can be upregulated by CX 3 CL1 produced by endothelial cells. CX 3 CL1 and several cytokines can bring CX 3 CR1 + T cells into blood vessels (30).
In atherosclerosis, monocyte is a crucial cell type involved in the development, maintenance, and resolution of atherosclerosis (31). Plaque formation, vascular accumulation, and activation of monocytes and foamy macrophages are initiated in the early development stage of atherosclerosis followed by plaque rupture, thrombosis progress, and chronic problems (32). CX 3 CR1 signal in monocyte can enhance the expression of anti-apoptotic factor B-cell lymphoma 2 (Bcl2) which is required for monocyte homeostasis and arteriosclerosis by promoting cell survival (33) . In granulomatosis with polyangitis (GPA) previously known as Wegener's granulomatosis (WG), CX 3 CR1 expressed in peripheral blood mononuclear cells can promote inflammation by promoting migration of leukocytes into inflammatory lesion (34) . In addition, Th1 cells expressing CX 3 CR1 are increased, thereby increasing Th1-related cytokines IFN-γ and IL-12 and promoting inflammation (35) . In patients with acquired aplastic anemia, expression levels of CX 3 CL1 and the number of T cells expressing CX 3 CR1 are increased. They can mediate the recruitment of T cells into bone marrow and destroy hematopoietic stem cells (30).
BRAIN AND NEURODEGENERATIVE DISEASES
In the brain, microglia and astrocytes express CX 3 CR1 in steady states. However, expression of CX 3 CR1 is increased by inflammatory stimulations ( Fig. 3 ) (36) . Microglia are originated from primitive myeloid progenitor during embryogenesis which begins with early hematopoiesis, unlike other brain cells (37) . Microglia is present in the CNS before neurons migrate to functional stage during development. Microglia can interact with neurons in adult brain. This is controlled by CX 3 CL1/CX 3 CR1 signaling (9) . In brain tissues, CX 3 CL1 is mostly expressed in neuron while microglia express CX 3 CR1, the unique receptor of CX 3 CL1. In microglia, CX 3 CR1 is involved in intracellular signaling pathways such as phospholipase C (PLC), PI3K, and ERK by recruiting transcription factors such as NF-κB and cyclic adenosine monophosphate response element binding protein (CREB) (38) . Microglia also play an important role in health and disease through CX 3 CL1/CX 3 CR1 signaling since neuroinflammation caused by hyperactivity of microglia is associated with neurodegenerative diseases such as Alzheimer's disease. In rat, administration of recombinant CX 3 CL1 can result in reduction of neurodegenerative disease (39) . In hepatic encephalopathy using azoxymethane treated mice model, injection of soluble CX 3 CL1 has resulted in the activation of microglia with decreased expression of IL-6 and TNF-α, thus alleviating hepatic encephalopathy (40). can secret cytokines and VEGF. This can lead to formation of extracellular matrix and vascular remodeling for angiogenesis. For inflammation, activation of CX 3 CR1 which is expressed in PBMCs causes leukocytes to migrate to the site of inflammation. CX 3 CR1-expressing Th1 also stimulates inflammation by secretion of IFN-γ and IL-12. For plaque, when CX 3 CL1 binds to CX 3 CR1 on monocyte, macrophage, and foam cells, these cells will accumulate in blood vessels and promote cell survival via expressing anti-apoptotic Bcl2 within cells. CX 3 CR1 is required for atherosclerosis. For aplastic anemia, autoreactive T cells expressing CX 3 CR1 are recruited into bone marrow by CX 3 CL1 to destroy HPSCs, resulting in aplastic anemia. VEGF, vascular endothelial growth factor; PBMC, peripheral blood mononuclear cell; HPSC, hematopoietic stem cell; EC, endothelial cell; HIF, hypoxia-inducible factor; MAPK, mitogen-activated protein kinase; GPA, granulomatosis with polyangiitis.
Alzheimer's disease might be caused by amyloid β (Aβ)-burdened neuron due to chronic inflammation and neurotoxicity (41) . In Aβ administration, CX 3 CR1 signaling is increased. Blocking CX 3 CR1 in microglia has resulted in reduced neurotoxicity by inhibiting the production of lactate dehydrogenase and cytotoxicity to hippocampal neurons (42) , although this remains controversial. M2-type microglia can promote Aβ plaque reduction by increasing phagocytic activity (43) . However, microglia can also increase tau propagation, another mechanism of Alzheimer's disease (44) . When a mild decrease in early CX 3 CL1/ CX 3 CR1 signaling occurs, phagocytosis of microglia increases and Aβ deposition clearance increases. However, severe reduction of CX 3 CL1/CX 3 CR1 signaling can result in abnormal regulation of microglia which may cause neuronal damage (45) . In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model for Parkinson's disease, CX 3 CL1 from neuron can inhibit the overexpression of pro-inflammatory molecules such as nitric oxide (NO) synthase, IL-1β, TNF-α, and IL-6 as well as α-synuclein, a possible causal factor for neurodegeneration (46) . Brain ischemia causes inflammation and activates microglia and macrophages, thus having both neuroprotective and harmful effects on the lesion (47) . In a middle cerebral artery occlusion (MCAO) mice model for brain ischemia, microglia and macrophages have adverse effects on neural recovery by inducing inflammatory responses using CX 3 CR1 . Activated microglia can play a neuroprotective role by stimulating the release of adenosine which can inhibit tau phosphorylation and Aβ clearance by phagocytosis. They can also change the activation state to M2-type which can induce anti-inflammatory cytokines. Activated microglia can also lead to neurotoxicity by inhibiting function of synaptic AMPAR and NMDA receptor (NR2B subunit). They can change the activation state to M1-type which promote pro-inflammatory cytokines and Aβ production. As Alzheimer's disease progresses, CX 3 CL1 expression is decreased while M1-type microglia are increased, resulting in enhanced neurotoxicity of microglia. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; NMDA, N-methyl-D-aspartate.
signaling in ischemic state (48). In addition, the number of CX 3 CR1 + bone marrow-derived mesenchymal stem cells (BMSCs) is increased. CX 3 CL1 seems to migrate BMSCs to ischemic brain lesions by activating Jak2-Stat5α-ERK1/2 pathway of CX 3 CR1 + BMSCs for neurogenesis (49) . However, inhibiting CX 3 CR1 expression by siRNA can decrease TNF-α and IL-1β cytokine production in a different ischemic animal model (50) . In spinal cord injury, microglia can migrate to the injury epicenter by CX 3 CR1 signaling while CX 3 CR1 increases inflammatory signaling of microglia (51) . Blocking CX 3 CR1 signaling can improve recovery from injury and decrease lesion pathology (52) .
CX 3 CR1 has a protective effect on autoimmune inflammation. CX 3 CR1 deficiency has resulted in increased production of IFN-γ and IL-17 followed by experimental autoimmune encephalomyelitis (EAE)-induced demyelination and nerve damage in cerebella and spinal cord (53) .
LUNG AND ASTHMA
Allergic asthma is a complex inflammatory disease characterized by various degrees of airflow obstruction, airway hypersensitivity, and inflammation, resulting in infiltration of mast cells, lymphocytes, and eosinophils (54) . The amount of CX 3 CL1 is known to be increased in asthmatic patients compared to that in healthy individuals. It can induce mast cell chemotaxis and increase CX 3 CR1 function in Th2 cells (55) . CX 3 CR1 in Th2 cells plays an important role in asthma (56) . CX 3 CR1 deficient mice have shown reduced airway hyper-responsiveness, eosinophilia, and cytokine secretion. These results suggest that CX 3 CL1/CX 3 CR1 has potential to be used as a target to treat allergic asthma. CX 3 CL1/CX 3 CR1 interaction plays an important role in the pathophysiology of chronic obstructive pulmonary disease (COPD), a chronic disease in which mucus exudates accumulate in a narrow airway with destruction of lung parenchymal cells, resulting in enlargement of airspace (57) . In COPD model, CX 3 CL1 expression is increased (58) . The number of macrophages and T lymphocytes expressing CX 3 CR1 is also increased in lung parenchyma (59) .
In pulmonary infections, the role of CX 3 CR1 remains unclear. CX 3 CR1 deficient mice infected with Vaccinia virus have shown increased viral loads but decreased T cell responses, suggesting that CX 3 CR1 plays an important role in the protection of DCs against virus infection (60). One of major DC subtypes in the lung is CD11b high CD103 − DCs which express CX 3 CR1. CD11b high CD103 − DCs are differentiated from Ly6C low CCR2 low monocytes by CX 3 CR1 dependent mechanism. The population of DCs has been found to be significantly decreased in CX 3 CR1 deficient mice (61) . In some bacterial infections such as those caused by Mycobacterium tuberculosis and Francisella tularensis, deficiency of CX 3 CR1 does not significantly affect host survival (62) . CX 3 CR1 deficient mice have shown an increase of monocytes and neutrophils in lungs compared to WT mice in later stages of pulmonary tularemia. Similar outcomes are also observed in organ burden and survival period (62) . The unexpected increase of infiltrates in lungs of CX 3 CR1 deficient mice might be caused by interactions between CX 3 CL1 and other molecules similar to CX 3 CR1 since expression levels of CX 3 CL1 are increased in CX 3 CR1 deficient mice (63) .
Pulmonary arterial hypertension (PAH) is caused by obstruction of small pulmonary artery for a long-time due to dysfunction and proliferation of endothelial and vascular smooth muscle cells (64). Several studies have shown that inflammation contributes to the development and progression of PAH which might involve CX 3 CL1/CX 3 CR1 interaction 7/19 https://doi.org/10.4110/in.2018.18.e5
Tissue-specific Role of CX3CR1-CX3CL1 Axis https://immunenetwork.org (65) . Inhibiting CX 3 CR1 using drug or genetic modification has resulted in changes in monocyte recruitment, macrophage phenotype ratio, and inhibition of pulmonary-artery smooth muscle cell proliferation (65) . CX 3 CL1/CX 3 CR1 interaction can be associated with development of hypoxic-induced pulmonary hypertension. Under hypoxic condition, M2 macrophage predominantly proliferates. M2 macrophages can stimulate cytokine secretion and induce pulmonary vascular remodeling (66) . CX 3 CR1 deficiency has resulted in reduced M2 predominant proliferation in hypoxic challenge and balance with M1 macrophages (67) .
LIVER
In the liver, M2 macrophage and myeloid DC are important for regulation of inflammation. These cells are derived from CD16 + monocytes expressing CX 3 CR1 (Fig. 4) (68) . CX 3 CR1 is also expressed in Kupffer cells (also known as stellate macrophages) which are specialized macrophages located in the liver (69 all contribute to necrosis and inflammation. CX 3 CR1 expressing cells are also involved in the regulation of liver fibrosis (72) . CX 3 CR1 mediates essential survival signal for hepatic monocyte-derived macrophages by activating anti-apoptotic Bcl2 expression (73) . CX 3 CR1 limits liver fibrosis in vivo by controlling differentiation and survival of intrahepatic monocytes. CX 3 CL1 treatment can induce the expression of IL-10 and arginase-1 in Kupffer cells through CX 3 CR1, which in turn can suppress HSC activation (74) . CX 3 CL1-CX 3 CR1 interaction inhibits inflammatory properties in Kupffer cells/macrophages, resulting in decreased liver inflammation and fibrosis (75) . CX 3 CL1/CX 3 CR1 axis can promote IL-10-mediated anti-inflammatory actions of hepatic DCs (75) . Primary biliary cirrhosis is an autoimmune injury caused by chronic inflammation of Th1/Th17 (76) . Th1/Th17 can secrete IFN-γ or IL-17 which then upregulates CX 3 CL1. Correlation between primary biliary cirrhosis and CX 3 CL1 expression is significantly proportional (77) . CX 3 CL1 is a chemokine and cell adhesion molecule that can attract cells expressing CX 3 CR1. Therefore, T cells expressing CX 3 CR1 can transmigrate into inflamed tissue and produce inflammatory cytokines such as TNF-α and IFN-γ.
GUT AND IMMUNE TOLERANCE
In the gut, 2 major phenotypic populations of mucosal mononuclear phagocytes have now been proposed: conventional DC and macrophages. Most macrophages and some DC subsets express CX 3 CR1. SIRPα
+ or CD103 − DC subsets express low levels of CX 3 CR1 depending on Zbtb46 and Flt3L for development and differentiation (78) . They can migrate to intestinal draining lymph node depending on CCR7. They also present soluble antigen to naïve CD4 + T cells. In mice, lamina propria macrophages express classical macrophages markers such as CD11b, CD64, MERTK, and F4/80 as well as high levels of MHC II and CX 3 CR1 (79). In resting mucosa, the role of lamina propria CX 3 CR1
+ macrophage is to pass captured antigen via trans-epithelial dendrites or phagocytosis onto DC for transport to mesenteric lymph node (MLN) to prime immune responses like lamina propria DC (Fig.  5) (6) . These transepithelial dendrites can cross junctions between epithelial cells and participate in the clearance of entero-invasive pathogens through CX 3 CR1 dependent process, thereby regulating immune tolerance or inflammation to commensal and pathogenic bacteria (80) . CX 3 CR1-deficient animals have shown impaired Listeria clearance and higher susceptibility to Salmonella infection (80) . Deletion of CX 3 CR1 or CX 3 CL1 has resulted in a specific and significant reduction in lamina propria macrophages with decreased translocation of bacteria to MLNs and their ability to take up pathogens. These findings demonstrate that CX 3 CR1 is a specific marker for lamina propria macrophages and a critical component in maintaining lamina propria macrophage homeostasis (81) . However, it has also been reported that CX 3 CR1 deficient mice have normal numbers of intestinal macrophages (82) . + macrophages produce immunoregulatory cytokines such as IL-10 which can maintain macrophage inertia in an autocrine manner. It can also facilitate terminal differentiation and maintenance of Foxp3 + regulatory T cell (Treg) within the lamina propria (86) . At steady state, antigens sampling by CX 3 CR1
+ phagocytes can induce the differentiation of CD8 + T cells expressing IL-10 which can inhibit inflammatory CD4 + T cell activation (87) . Monocyte-derived CX 3 CR1
+ macrophages are possibly a subset of macrophages that can prime segmented filamentous bacteria (SFB)-specific T cells and direct Th17 cell differentiation (88) . Lack of CX 3 CR1 expression is associated with significantly altered intestinal microbiota composition which is linked to impaired intestinal barrier. CX 3 CR1 is a gatekeeper for intestinal barrier integrity to limit steatohepatitis by maintaining intestinal homeostasis in mice (89) . Inflammatory bowel disease (IBD) refers to chronic inflammatory disorders affecting the gastrointestinal tract. There are 2 main clinical forms of IBD: Crohn's disease that affects any part of the gastrointestinal tract and ulcerative colitis (UC) whose pathology is restricted to the colonic mucosa (90) . CX 3 CL1/CX 3 CR1 axis also plays important roles in IBD. In patients with Crohn's disease, there is a significant increase of CX 3 CL1 transcription in inflamed lesions compared to that in non-inflamed colonic mucosa (91) . CX 3 CR1-deficient and CX 3 CL1-deficient mice are relatively protected from dextran sulfate sodium (DSS)-induced acute colitis (92) 
CANCER
Tumor can be attacked by a variety of immune cells such as CD8 + T cell, B cell, NK cell, and macrophage involving CX 3 CL1 (96) . CX 3 CL1 expression on the surface of a tumor cell can facilitate antitumor immunity by inducing infiltration of T cells, NK cells, and DCs into tumor tissues (Fig. 6) (97, 98) . CX 3 CL1-expressing tumor can be more efficiently eliminated than non-expressing tumor. CX 3 CL1 induces T-cell-dependent antitumor immunity through chemoattraction and activation of DCs (97) . Clinical results have shown that patients with CX 3 CL1-expressing tumors have better prognosis than those with non-CX 3 CL1-expressing tumors (99) . On the other hand, CX 3 CL1 can enhance the cytotoxicity of NK cells. NK cells pretreated with CX 3 CL1 have shown more potent cytotoxicity whereas those pretreated with anti-CX 3 CL1 or anti-CX 3 CR1 antibodies have shown attenuated cytotoxicity (100). CX 3 CR1 also plays an important role in antitumor activity in tumor cells that do not express CX 3 CL1 on the cell surface (101) . Lung tumor mass of B16F10 melanoma without expressing CX 3 CL1 is increased in CX 3 CR1 deficient mice compared to that of normal mice. In addition, CX 3 CR1 deficient NK cells have shown decreased secretion of IFN-γ but increased IL-6 secretion (101). On the other hand, in some carcinomas, CX 3 CL1/CX 3 CR1 interaction does not affect antitumor activity. In OV-HM ovarian carcinoma which expresses CX 3 CL1, CX 3 CL1 attracts immune cells without invading the tumor (102). They only stay in surrounding blood vessels without exerting antitumor activity.
Myeloid-derived suppressor cell (MDSC) is an immature-myeloid cell that has immune regulating effect (103) . Similar to other myeloid cells, MDSCs express CX 3 CR1 on their surface (104) . In a human hepatocellular carcinoma model, migration of MDSC into the hypoxia region is mediated through CCL26/CX 3 CR1. Increased HIFs under hypoxia condition can increase the expression of CCL26 on the surface of cancer cells and promote the recruitment of MDSCs expressing CX 3 CR1 (105) . Taken together, these results indicate that CX 3 CR1-mediated antitumor effect varies for each carcinoma.
CONCLUSION
Among different classes of chemokines, fractalkine/CX 3 CL1 with unique functional and structural characteristics can participate in either inflammation or anti-inflammation. Tissue-specific CX 3 CL1/CX 3 CR1 axis contributes to progression of various diseases in a given tissue. However, therapeutics targeting CX 3 CL1 or CX 3 CR1 have not been developed yet for clinical use. Emerging role of CX 3 CL1/CX 3 CR1 axis provides evidence that it might be used as a potential therapeutic target to control cardiovascular diseases, allergic asthma, neurodegenerative diseases, cancers, and other diseases related to vascular inflammation. 
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